Trial Profile
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 19 Apr 2021 Planned End Date changed from 1 Apr 2022 to 1 Jan 2028.
- 04 Jun 2019 Results assessing HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 11 Jan 2019 Status changed from recruiting to active, no longer recruiting.